Hormonal
The ER22/23EK polymorphism is associated with increased lean body mass and muscle strength in young adult males, and reduced abdominal fat measures in young adult females, due to relative glucocorticoid resistance.
For young adults carrying the ER22/23EK variant, your body composition may naturally favor higher muscle mass in men and lower abdominal fat in women. This is a genetic advantage. Focus on resistance training to maximize this potential in men, and maintain a healthy lifestyle to preserve this favorable fat distribution in women.
In males aged 36 and 32 years, we found ER22/23EK carriers to be, on average, 5 cm taller... lean body mass was significantly higher in male carriers... muscle strength... also was significantly greater. In females... Waist circumferences tended to be smaller in female ER22/23EK carriers at young-adult age.
Why this rating
Consistent findings in a longitudinal cohort study from age 13 to 36.
Source
Polymorphisms in the Glucocorticoid Receptor Gene and Their Associations with Metabolic Parameters and Body Composition
Elisabeth F. C. van Rossum · Recent Progress in Hormone Research · 2004
DOI 10.1210/rp.59.1.333
More from this paper
- The ER22/23EK polymorphism in the glucocorticoid receptor gene confers relative resistance to glucocorticoids, resulting in a healthier metabolic profile characterized by lower fasting insulin, increased insulin sensitivity, and lower cholesterol levels.Good
- The ER22/23EK polymorphism is associated with a lower risk of dementia, fewer white matter lesions, and significantly better survival rates in the elderly.Good
- The N363S polymorphism is associated with increased glucocorticoid sensitivity, higher BMI, and increased insulin response to dexamethasone, though associations with BMI are controversial across different populations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →